Previous 10 | Next 10 |
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancem...
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VAN...
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which are not yet availa...
THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and eve appetite, weight/BMI. In fact, in a study of 900 adults aged 21 and older in the U.S., InMed Pharmaceuticals Inc.’s (NASDAQ: INM) subsidiary, BayMedica, will be providing rare can...
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science Inc.’s Radicle Energy ra...
Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedica Assesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on cannabinoids for consumers, brands and healthcare provide...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its...
LONDON, UK / ACCESSWIRE / May 3, 2022 / InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provid...
Cannabinoids, such as cannabidivarin (CBDV) could be a therapeutic game-changer. In fact, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “Cannabinoids hold tremendous therapeutic potential t...
Expands library of proprietary cannabinoid analogs for pharma R&D Research collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals I...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...